Do analysts prefer ABC or ONT?

Oxford Nanopore Technologies has a consensus price target of GBX 198.60, indicating a potential downside of 13.95%. Given Abcam's higher probable upside, equities research analysts clearly believe Abcam is more favorable than Oxford Nanopore Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83

Does the media refer more to OXB or ONT?

In the previous week, Oxford Biomedica had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 4 mentions for Oxford Biomedica and 2 mentions for Oxford Nanopore Technologies. Oxford Biomedica's average media sentiment score of 0.47 beat Oxford Nanopore Technologies' score of 0.16 indicating that Oxford Biomedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Nanopore Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SLN or ONT?

Oxford Nanopore Technologies has a consensus target price of GBX 198.60, suggesting a potential downside of 13.95%. Given Silence Therapeutics' higher possible upside, research analysts plainly believe Silence Therapeutics is more favorable than Oxford Nanopore Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83

Does the media favor ONT or AVCT?

In the previous week, Avacta Group had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Avacta Group and 2 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.16 beat Avacta Group's score of -0.24 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Nanopore Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oxford Nanopore Technologies (ONT) Competitors

GBX 231.47 +17.47 (+8.16%)

As of 12:31 PM Eastern

Compare

ONT vs. OBI, ABC, OXB, SLN, and AVCT

Should you buy Oxford Nanopore Technologies stock or one of its competitors? Oxford Nanopore Technologies's main competitors and comparable companies include Ondine Biomedical (OBI), Abcam (ABC), Oxford Biomedica (OXB), Silence Therapeutics (SLN), and Avacta Group (AVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Ondine Biomedical?

Oxford Nanopore Technologies (LON:ONT) and Ondine Biomedical (LON:OBI) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Oxford Nanopore Technologies has a net margin of -54.66% compared to Ondine Biomedical's net margin of -1,150.26%. Oxford Nanopore Technologies' return on equity of -35.45% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%
Ondine Biomedical	-1,150.26%	-24,731.60%	-159.71%

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 32.8% of Ondine Biomedical shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Comparatively, 29.0% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oxford Nanopore Technologies has a beta of 0.964, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.298, indicating that its stock price is 70% less volatile than the broader market.

Ondine Biomedical has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£235M	9.60	-£175.21M	-£12.50	N/A
Ondine Biomedical	C$2.88M	1,760.12	-C$424.66K	-C$6.00	N/A

In the previous week, Oxford Nanopore Technologies had 2 more articles in the media than Ondine Biomedical. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 0 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 0.30 beat Oxford Nanopore Technologies' score of 0.16 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Neutral
Ondine Biomedical	Neutral

Oxford Nanopore Technologies currently has a consensus target price of GBX 198.60, indicating a potential downside of 13.95%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 9 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Abcam?

Abcam (LON:ABC) and Oxford Nanopore Technologies (LON:ONT) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

In the previous week, Oxford Nanopore Technologies had 2 more articles in the media than Abcam. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 0 mentions for Abcam. Oxford Nanopore Technologies' average media sentiment score of 0.16 beat Abcam's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Abcam	Neutral
Oxford Nanopore Technologies	Neutral

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	£350.40M	0.00	N/A	£0.06	N/A
Oxford Nanopore Technologies	£235M	9.60	-£175.21M	-£12.50	N/A

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oxford Nanopore Technologies has a consensus price target of GBX 198.60, indicating a potential downside of 13.95%. Given Abcam's higher probable upside, equities research analysts clearly believe Abcam is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%

Summary

Abcam beats Oxford Nanopore Technologies on 7 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Oxford Biomedica currently has a consensus price target of GBX 580.85, suggesting a potential upside of 6.77%. Oxford Nanopore Technologies has a consensus price target of GBX 198.60, suggesting a potential downside of 13.95%. Given Oxford Biomedica's higher probable upside, equities research analysts clearly believe Oxford Biomedica is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Oxford Biomedica has a net margin of -23.23% compared to Oxford Nanopore Technologies' net margin of -54.66%. Oxford Nanopore Technologies' return on equity of -35.45% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-23.23%	-54.51%	-12.67%
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%

Oxford Biomedica has a beta of 1.092, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.964, suggesting that its share price is 4% less volatile than the broader market.

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 18.9% of Oxford Nanopore Technologies shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£175.36M	3.76	-£143.51M	-£26.92	N/A
Oxford Nanopore Technologies	£235M	9.60	-£175.21M	-£12.50	N/A

In the previous week, Oxford Biomedica had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 4 mentions for Oxford Biomedica and 2 mentions for Oxford Nanopore Technologies. Oxford Biomedica's average media sentiment score of 0.47 beat Oxford Nanopore Technologies' score of 0.16 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Nanopore Technologies (LON:ONT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Silence Therapeutics has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Oxford Nanopore Technologies	£235M	9.60	-£175.21M	-£12.50	N/A

In the previous week, Oxford Nanopore Technologies had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 0 mentions for Silence Therapeutics. Oxford Nanopore Technologies' average media sentiment score of 0.16 beat Silence Therapeutics' score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Oxford Nanopore Technologies	Neutral

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oxford Nanopore Technologies has a consensus target price of GBX 198.60, suggesting a potential downside of 13.95%. Given Silence Therapeutics' higher possible upside, research analysts plainly believe Silence Therapeutics is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Avacta Group?

Oxford Nanopore Technologies (LON:ONT) and Avacta Group (LON:AVCT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Oxford Nanopore Technologies has a net margin of -54.66% compared to Avacta Group's net margin of -35,730.97%. Oxford Nanopore Technologies' return on equity of -35.45% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

Oxford Nanopore Technologies has a beta of 0.964, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

In the previous week, Avacta Group had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Avacta Group and 2 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.16 beat Avacta Group's score of -0.24 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avacta Group has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£235M	9.60	-£175.21M	-£12.50	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Comparatively, 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oxford Nanopore Technologies currently has a consensus price target of GBX 198.60, suggesting a potential downside of 13.95%. Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Avacta Group beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONT vs. The Competition

Export

Metric	Oxford Nanopore Technologies	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£2.26B	£3.83B	£7.11B	£2.80B
Dividend Yield	N/A	3.64%	2.53%	6.18%
P/E Ratio	-18.52	13.45	274.71	366.17
Price / Sales	9.63	1,284.75	600.46	89,425.29
Price / Cash	4.04	121.76	77.38	27.89
Price / Book	3.45	16.62	10.93	6.83
Net Income	-£175.21M	-£22.67M	£3.50B	£5.89B
7 Day Performance	31.12%	-3.21%	-2.21%	-0.75%
1 Month Performance	39.94%	-10.88%	-6.45%	16.84%
1 Year Performance	51.29%	21.05%	8.70%	16.40%

Oxford Nanopore Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONT Oxford Nanopore Technologies	1.8241 of 5 stars	GBX 231.47 +8.2%	GBX 198.60 -14.2%	+36.5%	£2.26B	£235M	N/A	1,314
OBI Ondine Biomedical	N/A	C$10.75 flat	N/A	-32.8%	C$5.59B	C$2.65M	N/A	N/A	News Coverage Gap Down
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
OXB Oxford Biomedica	2.1423 of 5 stars	GBX 492 -0.2%	GBX 580.85 +18.1%	-13.6%	£595.56M	£168.74M	N/A	891	Gap Up
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. OBI, ABC, OXB, SLN, and AVCT

How does Oxford Nanopore Technologies compare to Ondine Biomedical?

Summary

How does Oxford Nanopore Technologies compare to Abcam?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Summary

How does Oxford Nanopore Technologies compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. OBI, ABC, OXB, SLN, and AVCT

How does Oxford Nanopore Technologies compare to Ondine Biomedical?

Is ONT or OBI more profitable?

Do institutionals & insiders believe in ONT or OBI?

Which has more risk & volatility, ONT or OBI?

Which has higher earnings and valuation, ONT or OBI?

Does the media refer more to ONT or OBI?

Do analysts rate ONT or OBI?

Summary

How does Oxford Nanopore Technologies compare to Abcam?

Does the media refer more to ABC or ONT?

Which has higher valuation & earnings, ABC or ONT?

Do institutionals & insiders hold more shares of ABC or ONT?

Do analysts prefer ABC or ONT?

Is ABC or ONT more profitable?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Do analysts recommend OXB or ONT?

Is OXB or ONT more profitable?

Which has more risk & volatility, OXB or ONT?

Do institutionals & insiders hold more shares of OXB or ONT?

Which has better valuation and earnings, OXB or ONT?

Does the media refer more to OXB or ONT?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Which has preferable earnings & valuation, SLN or ONT?

Does the media prefer SLN or ONT?

Do insiders & institutionals hold more shares of SLN or ONT?

Do analysts rate SLN or ONT?

Is SLN or ONT more profitable?

Summary

How does Oxford Nanopore Technologies compare to Avacta Group?

Is ONT or AVCT more profitable?

Which has more risk & volatility, ONT or AVCT?

Does the media favor ONT or AVCT?

Which has preferable valuation & earnings, ONT or AVCT?

Do insiders and institutionals have more ownership in ONT or AVCT?

Do analysts rate ONT or AVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools